NCT05445921View on ClinicalTrials.gov

Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 12, 2022

Study Completion Date

December 12, 2022

Conditions
AnosmiaHyposmiaParosmiaOlfactory Disorder
Interventions
DRUG

Stellate Ganglion Block

The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.

Trial Locations (1)

63110

Washington University School of Medicine/Barnes Jewish Hospital, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER